Biogenvs.Incyte
BIIB vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 1.4× larger than Incyte by market cap; Incyte trades at the lower P/E (14.0 vs 38.4); year to date, Biogen leads (+26.2% vs +14.9%).
Side by side
| BIIB | INCY | |
|---|---|---|
| Market cap | $32.1B | $22.5B |
| Price | $218.43 | $112.75 |
| Today | −1.7% | −0.6% |
| Return YTD | +26.2% | +14.9% |
| Return 1Y | +45.9% | +30.1% |
| Since June 26, 2026 | +1.1% | −0.9% |
| P/E | 38.4 | 14.0 |
| P/S | 3.2 | 3.9 |
| P/B | 1.7 | 3.5 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More BIIB & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.